AVITA Medical (RCEL) Resumen de Acciones
AVITA Medical, Inc. junto con sus filiales, opera como empresa de cuidados terapéuticos de heridas agudas en Estados Unidos, Japón, la Unión Europea, Australia y el Reino Unido. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 0/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
RCEL Community Fair Values
Create NarrativeSee what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de AVITA Medical, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$4.44 |
| Máximo en las últimas 52 semanas | US$7.12 |
| Mínimo de 52 semanas | US$3.22 |
| Beta | 1.86 |
| Cambio en 1 mes | 7.51% |
| Variación en 3 meses | 0% |
| Cambio de 1 año | -16.23% |
| Variación en 3 años | -76.21% |
| Variación en 5 años | -76.52% |
| Variación desde la OPV | -82.24% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 27
RCEL: Execution And Cash Strength Will Support Recovery And Multiple Expansion
Analysts have lifted their price targets on AVITA Medical stock from about $6 to $12. They point to continued uptake of RECELL, expectations for steady organic revenue growth with solid margins, and sufficient support for the company’s working capital needs as key factors behind the shift.
Actualización de narrativa • Jul 13
RCEL: Renewed Adoption Confidence Will Support Future Bullish Repricing
Analysts have raised their consolidated price target for AVITA Medical from $5.50 to $12, pointing to renewed confidence in RECELL adoption, expectations for organic revenue momentum, and views that the company has sufficient flexibility to support working capital needs. Analyst Commentary Recent research on AVITA Medical highlights a cluster of upbeat views around RECELL adoption, revenue momentum, and balance sheet flexibility, but also leaves room for questions about how consistently the company can execute against expectations.Actualización de narrativa • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Recent updates
Actualización de narrativa • Jul 27
RCEL: Execution And Cash Strength Will Support Recovery And Multiple Expansion
Analysts have lifted their price targets on AVITA Medical stock from about $6 to $12. They point to continued uptake of RECELL, expectations for steady organic revenue growth with solid margins, and sufficient support for the company’s working capital needs as key factors behind the shift.Actualización de narrativa • Jul 13
RCEL: Renewed Adoption Confidence Will Support Future Bullish Repricing
Analysts have raised their consolidated price target for AVITA Medical from $5.50 to $12, pointing to renewed confidence in RECELL adoption, expectations for organic revenue momentum, and views that the company has sufficient flexibility to support working capital needs. Analyst Commentary Recent research on AVITA Medical highlights a cluster of upbeat views around RECELL adoption, revenue momentum, and balance sheet flexibility, but also leaves room for questions about how consistently the company can execute against expectations.Actualización de narrativa • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Actualización de narrativa • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Actualización de narrativa • May 31
RCEL: Market Recovery And Cash Progress Are Expected To Drive Upside
Analysts have slightly adjusted the AVITA Medical price target to reflect updated assumptions for growth, margins and future P/E. They continue to reference Street research that highlights improving execution, Lake Street’s higher $6 target, and Northland's $10 target supported by expectations for revenue recovery, cash progress and a large addressable market.
Actualización de narrativa • May 10
RCEL: Low Market Penetration And FY27 Cash Breakeven Will Drive Repricing
Analysts have trimmed their price target for AVITA Medical to $5.49 from $5.52, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E after recent research highlighted low current market penetration, a roughly $1.3b total addressable market, reimbursement stabilization, and an outlook for potential cash breakeven during FY27. Analyst Commentary Recent research points to a mixed backdrop for AVITA Medical, with analysts updating their models around a roughly $1.3b total addressable market, low current market penetration of about 5%, and expectations tied to reimbursement trends and the path toward a potential cash breakeven during FY27.Actualización de narrativa • Apr 25
RCEL: Market Penetration And Burn Preparedness Agreement Will Support Constructive Upside
Narrative Update on AVITA Medical The Analyst Price Target for AVITA Medical has been adjusted from $10.02 to about $10.16. Analysts point to updated views on revenue growth and profit margins, as well as recent Northland research highlighting market penetration, product differentiation, reimbursement trends and the path toward cash breakeven as key supports for this change.Actualización de narrativa • Apr 11
RCEL: Reimbursement Stability And FY27 Cash Breakeven Frame Balanced Risk Reward Outlook
The analyst price target for AVITA Medical has been revised slightly higher to reflect an updated fair value of about $5.52, up from roughly $5.33. Analysts point to expectations for revenue growth, stable profit margins, and recent research citing product differentiation, reimbursement stabilization, and progress toward cash breakeven as key drivers of their refreshed view.Actualización de narrativa • Mar 28
RCEL: Reimbursement Stability And FY27 Cash Breakeven Drive Bullish Rerating Potential
Analysts have trimmed their blended valuation for AVITA Medical, with the updated fair value estimate easing from about $5.44 to $5.33 per share. This reflects revised assumptions on revenue growth, profit margins, and a lower future P/E multiple informed by recent research that highlights both the pullback in the stock and expectations for double digit top line expansion over time.Actualización de narrativa • Mar 13
RCEL: Reimbursement Stability And Cash Breakeven Path Will Underpin Renewed Market Confidence
Analysts have lifted their AVITA Medical price target to $10, supported by expectations for renewed double digit revenue growth from a roughly $1.3b addressable market, reimbursement stabilization, and a path to potential cash breakeven around FY27. Analyst Commentary Recent coverage has highlighted a mixed but generally constructive view on AVITA Medical, with the latest initiation pointing to a $10 price target.Actualización de narrativa • Feb 27
RCEL: Refined Earnings Assumptions And Burn Data Will Support Constructive Upside
Analysts have nudged their average price target on AVITA Medical up by $0.50 per share, citing updated assumptions around revenue growth, profit margins and P/E multiples that modestly refine their valuation models. Analyst Commentary Recent bullish analysts have framed the $0.50 uplift in the average price target as a refinement rather than a wholesale reset.Actualización de narrativa • Feb 13
RCEL: Ongoing Burn And Wound Data Will Support Constructive Long-Term Upside
Analysts have adjusted their price target on AVITA Medical to $10.07 from $14.10, reflecting updated views on fair value, discount rate, revenue growth and profit margin assumptions that are broadly consistent with recent Street research, including the modest target raise cited by Lake Street. Analyst Commentary Recent price target work on AVITA Medical points to a more constructive tone among bullish analysts, even if some models still embed conservative assumptions on execution and profitability.Actualización de narrativa • Jan 30
RCEL: Elevated Expectations For 2026 Guidance Will Expose Fragile Market Confidence
Narrative Update: AVITA Medical Analysts have raised their price target on AVITA Medical to about US$3.61 from roughly US$3.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E as key factors behind the revised assessment. Analyst Commentary Even with a higher price target around US$3.61, bearish analysts remain cautious and describe the move as a fine tuning of assumptions rather than a strong endorsement of upside potential.Artículo de análisis • Jan 24
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Actualización de narrativa • Jan 16
RCEL: Two Year Revenue Guidance Reset Will Support Bullish Repricing
Analysts have adjusted their price target for AVITA Medical, reflecting a lower implied fair value of $6.98, down from $7.32. They cite updated assumptions around revenue growth, profit margins, and a reduced future P/E multiple.Artículo de análisis • Nov 09
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
AVITA Medical, Inc. ( NASDAQ:RCEL ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Actualización de narrativa • Nov 08
RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery
Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.Artículo de análisis • Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Actualización de narrativa • Sep 17
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.Actualización de narrativa • Aug 15
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.Artículo de análisis • Aug 10
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Unfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 25% in the last...Artículo de análisis • May 29
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
Key Insights AVITA Medical will host its Annual General Meeting on 4th of June CEO Jim Corbett's total compensation...
Nueva narrativa • Apr 24
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Artículo de análisis • Mar 06
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
AVITA Medical, Inc.'s ( NASDAQ:RCEL ) price-to-sales (or "P/S") ratio of 3.5x might make it look like a strong buy...Artículo de análisis • Dec 30
Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Rentabilidad de los accionistas
| RCEL | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -3.7% | 0.5% | -2.6% |
| 1Y | -16.2% | 31.8% | 14.3% |
Rentabilidad vs. Industria: Los resultados de RCEL fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 31.8% el año pasado.
Rentabilidad vs. Mercado: RCEL obtuvo unos resultados inferiores a los del mercado US, que fueron del 14.3% el año pasado.
Volatilidad de los precios
| RCEL volatility | |
|---|---|
| RCEL Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: RCEL no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de RCEL (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 226 | Cary Vance | avitamedical.com |
AVITA Medical, Inc. junto con sus filiales, opera como empresa de cuidados terapéuticos de heridas agudas en Estados Unidos, Japón, la Unión Europea, Australia y el Reino Unido. El principal producto de la empresa es el sistema RECELL, un dispositivo de recolección de células utilizado para el tratamiento de heridas por quemaduras térmicas y defectos cutáneos de espesor total, así como para la repigmentación de lesiones de vitíligo despigmentadas estables. También ofrece el dispositivo de recolección de células autólogas RECALL, que puede tratar áreas de hasta 1.920 cm2; el dispositivo de recolección de células autólogas RECELL con facilidad de uso, un dispositivo mejorado de facilidad de uso que puede tratar áreas de hasta 1.920 cm²; y RECELL GO mini autologous cell harvesting device, una extensión de línea del sistema RECELL GO para tratar heridas más pequeñas de hasta 480 cm2, así como RECELL GO autologous cell harvesting device, que consta de RECELL GO processing device, que controla y gestiona la presión aplicada para disgregar las células de la piel del donante y controla el tiempo de incubación de la enzima RECELL para optimizar el rendimiento celular y promover la viabilidad celular; y RECELL GO preparation kit, que puede tratar áreas de hasta 1.920 cm2.
Resumen de fundamentos de AVITA Medical, Inc.
| Estadísticas fundamentales de RCEL | |
|---|---|
| Capitalización bursátil | US$136.68m |
| Beneficios(TTM) | -US$45.34m |
| Ingresos (TTM) | US$72.35m |
1.9x
Ratio precio-ventas (PS)-3.0x
Ratio precio-beneficio (PE)¿Está RCEL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de RCEL | |
|---|---|
| Ingresos | US$72.35m |
| Coste de los ingresos | US$13.48m |
| Beneficio bruto | US$58.86m |
| Otros gastos | US$104.20m |
| Beneficios | -US$45.34m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 06, 2026
| Beneficios por acción (BPA) | -1.47 |
| Margen bruto | 81.36% |
| Margen de beneficio neto | -62.67% |
| Ratio deuda/patrimonio | -199.2% |
¿Cómo se ha desempeñado RCEL a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/30 11:04 |
| Precio de las acciones al final del día | 2026/07/29 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AVITA Medical, Inc. está cubierta por 13 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |